Literature DB >> 10692564

The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions.

M P Saunders1, M Jaffar, A V Patterson, J Nolan, M A Naylor, R M Phillips, A L Harris, I J Stratford.   

Abstract

Analogues of EO9 (3-hydroxymethyl-5-aziridinyl-1-methyl-2[1H-indole-4-7-dione]prop-2-e n-1-ol) which lack functionality at either the C-2 or C-3 position were synthesised. The aim was to establish the importance of each group towards toxicity and to give an indication as to whether substitution at either position altered activation and toxicity after metabolism by cellular NADPH: cytochrome c (P450) reductase (P450R). MDA231 breast cancer cells were transfected with the cDNA for human P450R and stable clones were isolated. These high P450R-expressing clones were used to determine the aerobic and hypoxic toxicity of EO9 and the two analogues that lacked functionality at either C-2 or C-3. The results showed that P450R was strongly implicated in the bioactivation of EO9 and its analogues under both of these conditions. This data also showed that the C-3 functionality was primarily implicated in hypoxic toxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10692564     DOI: 10.1016/s0006-2952(99)00405-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.

Authors:  P M Loadman; M C Bibby; R M Phillips
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

Review 2.  Modulation of the tumor vasculature and oxygenation to improve therapy.

Authors:  Dietmar W Siemann; Michael R Horsman
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

3.  Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity.

Authors:  Ayelet M Samuni; William DeGraff; Murali C Krishna; James B Mitchell
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

4.  Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.

Authors:  Jiechuang Su; Yongchuan Gu; Frederik B Pruijn; Jeff B Smaill; Adam V Patterson; Christopher P Guise; William R Wilson
Journal:  J Biol Chem       Date:  2013-11-06       Impact factor: 5.157

5.  Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).

Authors:  Chao Yan; Jadwiga K Kepa; David Siegel; Ian J Stratford; David Ross
Journal:  Mol Pharmacol       Date:  2008-09-15       Impact factor: 4.436

6.  A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.

Authors:  G A Choudry; P A Stewart; J A Double; M R Krul; B Naylor; G M Flannigan; T K Shah; J E Brown; R M Phillips
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

7.  Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.

Authors:  Linda Spiegelberg; Ruud Houben; Raymon Niemans; Dirk de Ruysscher; Ala Yaromina; Jan Theys; Christopher P Guise; Jeffrey B Smaill; Adam V Patterson; Philippe Lambin; Ludwig J Dubois
Journal:  Clin Transl Radiat Oncol       Date:  2019-01-18

8.  Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle x-ray scattering.

Authors:  Jacqueline Ellis; Aldo Gutierrez; Igor L Barsukov; Wei-Cheng Huang; J Günter Grossmann; Gordon C K Roberts
Journal:  J Biol Chem       Date:  2009-10-26       Impact factor: 5.157

Review 9.  Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

Authors:  Christopher P Guise; Alexandra M Mowday; Amir Ashoorzadeh; Ran Yuan; Wan-Hua Lin; Dong-Hai Wu; Jeff B Smaill; Adam V Patterson; Ke Ding
Journal:  Chin J Cancer       Date:  2013-07-12

Review 10.  ABC transporters in CSCs membranes as a novel target for treating tumor relapse.

Authors:  Laura Zinzi; Marialessandra Contino; Mariangela Cantore; Elena Capparelli; Marcello Leopoldo; Nicola A Colabufo
Journal:  Front Pharmacol       Date:  2014-07-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.